Literature DB >> 6796294

Abnormal hypothalamic-pituitary function in polyostotic fibrous dysplasia.

J Albin, R Wu.   

Abstract

Hypothalamic-pituitary dysfunction was found in two patients with polyostotic fibrous dysplasia and leontiasis ossea. Both patients probably had McCune--Albright syndrome with early sexual development, disfiguring craniofacial bone lesions, cutaneous hyperpigmentation and gigantism in childhood. Endocrinological studies revealed measurable plasma growth hormone throughout a 24-h sampling period with preservation of sleep augmented rises. The mean 24-h values were 329 and 7 ng/ml, respectively. Both their mean plasma prolactin concentrations, 385 and 45 ng/ml, and the 24-h secretory patterns of prolactin were abnormal. One patient had an elevated mean plasma cortisol concentration of 8.5 micrograms/dl but the 24-h pattern of cortisol secretion was normal. Basal plasma LH, FSH, TSH, T4 and T3 concentrations were normal but neither patient had a TSH response to TRH. Prolactin and growth hormone secretions were, however, increased after TRH. Oral glucose resulted in partial suppression of GH but an exaggerated insulin response in both patients. Post-mortem in one patient revealed a thick calvarium with bony encasement of the pituitary gland. The pituitary and hypothalamus appeared normal on gross, light microscopic and electronmicroscopic examination. These data strongly suggest the presence of hypothalamic-pituitary dysfunction in these two patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796294     DOI: 10.1111/j.1365-2265.1981.tb00632.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  8 in total

1.  Polyostotic fibrous dysplasia with contrasting responses to calcitonin and mithramycin: aetiological and therapeutic implications.

Authors:  A Long; T Loughlin; R P Towers; T J McKenna
Journal:  Ir J Med Sci       Date:  1988-07       Impact factor: 1.568

2.  Arginine induced growth hormone (hGH) response and paradoxical hGH secretion stimulated by TRH in diabetes mellitus.

Authors:  G Winkler; L Gerö; T Halmos; A Grósz; G Gefferth; P Varga; G Tamás
Journal:  Acta Diabetol Lat       Date:  1987 Apr-Jun

3.  Octreotide therapy of growth hormone excess in the McCune-Albright syndrome.

Authors:  S I Sherman; P W Ladenson
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

4.  Acromegaly, multinodular goiter and silent polyostotic fibrous dysplasia. A variant of the McCune-Albright syndrome.

Authors:  R Abs; A Beckers; F L Van de Vyver; A De Schepper; A Stevenaert; G Hennen
Journal:  J Endocrinol Invest       Date:  1990-09       Impact factor: 4.256

5.  Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis.

Authors:  K Kovacs; E Horvath; M O Thorner; A D Rogol
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1984

Review 6.  Acromegaly and McCune-Albright syndrome.

Authors:  Sylvie Salenave; Alison M Boyce; Michael T Collins; Philippe Chanson
Journal:  J Clin Endocrinol Metab       Date:  2014-02-11       Impact factor: 5.958

Review 7.  Clinical Characteristics and Management of Patients With McCune-Albright Syndrome With GH Excess and Precocious Puberty: A Case Series and Literature Review.

Authors:  Xiao Zhai; Lian Duan; Yong Yao; Bing Xing; Kan Deng; Linjie Wang; Feng Feng; Zhiyong Liang; Hui You; Hongbo Yang; Lin Lu; Shi Chen; Renzhi Wang; Hui Pan; Huijuan Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-10-29       Impact factor: 5.555

8.  Craniofacial polyostotic fibrous dysplasia: A rare case.

Authors:  Fatemeh Owlia; Mohammad-Hassan Akhavan Karbassi
Journal:  Dent Res J (Isfahan)       Date:  2014-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.